# Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

> **NCT00642499** · PHASE2 · COMPLETED · sponsor: **Solvay Pharmaceuticals** · enrollment: 103 (actual)

## Conditions studied

- Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting
- HIV Infections

## Interventions

- **DRUG:** Dronabinol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00642499
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2008-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00642499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00642499, "Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00642499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*